These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33078652)

  • 41. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
    Kim KH; Jung YJ; Lee Y; Park BR; Oh J; Lee YN; Kim MC; Jeeva S; Kang SM
    Virology; 2020 Nov; 550():51-60. PubMed ID: 32882637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge.
    Kuenstling TE; Sambol AR; Hinrichs SH; Larson MA
    Sci Rep; 2018 Aug; 8(1):11856. PubMed ID: 30087372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice.
    Liu Q; Liu K; Xue C; Zhou J; Li X; Luo D; Zheng J; Xu S; Liu GD; Cao Y
    Vaccine; 2014 May; 32(25):3041-9. PubMed ID: 24704333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.
    Price JV; Jarrell JA; Furman D; Kattah NH; Newell E; Dekker CL; Davis MM; Utz PJ
    PLoS One; 2013; 8(5):e64555. PubMed ID: 23734205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective Efficacy of an Orf Virus-Vector Encoding the Hemagglutinin and the Nucleoprotein of Influenza A Virus in Swine.
    Joshi LR; Knudsen D; Piñeyro P; Dhakal S; Renukaradhya GJ; Diel DG
    Front Immunol; 2021; 12():747574. PubMed ID: 34804030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine.
    Dzimianski JV; Han J; Sautto GA; O'Rourke SM; Cruz JM; Pierce SR; Ecker JW; Carlock MA; Nagashima KA; Mousa JJ; Ross TM; Ward AB; DuBois RM
    Commun Biol; 2023 Apr; 6(1):454. PubMed ID: 37185989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
    Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
    J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus.
    Sun X; Liu C; Lu X; Ling Z; Yi C; Zhang Z; Li Z; Jin M; Wang W; Tang S; Wang F; Wang F; Wangmo S; Chen S; Li L; Ma L; Zhang Y; Yang Z; Dong X; Qian Z; Ding J; Wang D; Cong Y; Sun B
    Nat Commun; 2022 May; 13(1):2378. PubMed ID: 35501328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection.
    Zeng D; Xin J; Yang K; Guo S; Wang Q; Gao Y; Chen H; Ge J; Lu Z; Zhang L; Chen J; Chen Y; Xia N
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One HA stalk topping multiple heads as a novel influenza vaccine.
    Zhou P; Qiu T; Wang X; Yang X; Shi H; Zhu C; Dai W; Xing M; Zhang X; Xu J; Zhou D
    Emerg Microbes Infect; 2024 Dec; 13(1):2290838. PubMed ID: 38044872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
    Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
    Edgar JE; Trezise S; Anthony RM; Krammer F; Palese P; Ravetch JV; Bournazos S
    Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2314905120. PubMed ID: 37871218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
    Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
    Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model.
    Vergara-Alert J; Argilaguet JM; Busquets N; Ballester M; Martín-Valls GE; Rivas R; López-Soria S; Solanes D; Majó N; Segalés J; Veljkovic V; Rodríguez F; Darji A
    PLoS One; 2012; 7(7):e40524. PubMed ID: 22815759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
    Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
    Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.